Dear WIPO Re:Search Members and Friends,

Happy New Year!

While it may only be January, 2019 is shaping up to be an impactful year, with many WIPO Re:Search projects advancing through research and product development milestones. Building on the success of 2018, we look forward to establishing new and promising R&D collaborations across our growing network of Members this year. Keep an eye out for our 2018 WIPO Re:Search Partnership Hub Annual Report in February.

Through the WIPO Re:Search Australian Government-Funded Fellowship Program, BVGH is coordinating the placement of five additional scientists from East Africa and the Indo-Pacific region at advanced research institutions and companies – including the Burnet Institute, the Griffith Institute for Drug Discovery, Johnson & Johnson, PATH, University of California, San Diego, and University of Melbourne.

Together with our partner WIPO, we will continue to highlight the Consortium’s successes and impacts through the new WIPO Re:Search Resource Platform, this newsletter, other online and print materials, international presentations, and social media. BVGH will also begin development of our third WIPO Re:Search Partnership Storybook. View the last Storybook here.

As we dive into the New Year, BVGH thanks you for your continued support and participation in WIPO Re:Search. As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH
Cornerstones of Collaboration

Johnson & Johnson Shares Compounds to Aid in Malaria Research

Johnson & Johnson has provided Drs. Audrey Odom John and Paul Hruz at Washington University, St. Louis with its Jump-stARter library to screen against P. falciparum, the most deadly species of malaria parasite. Drs. Odom John and Hruz have developed a novel platform to selectively screen compounds’ ability to inhibit parasite glucose transport.

BVGH FundFinder Featured Award

NIH U.S.-Brazil Collaborative Biomedical Research Program

The purpose of this funding opportunity is to promote collaborative biomedical research between the United States (U.S.) and Brazil. Research areas supported under this program include allergy, immunology, and infectious diseases, including Chagas disease, dengue, leishmaniasis, leprosy, malaria, schistosomiasis, soil-transmitted helminthiases, tuberculosis, and HIV/AIDS and its co-morbidities; neurological disorders and stroke; and environmental health sciences.

- **Funding Amount:** Maximum of $175,000 direct costs per year - *Maximum project period is 4 years*
- **Funder:** National Institutes of Health (NIH)
- **Deadline:** Letters of intent due February 8, 2019
- **Eligibility:** Partnerships between U.S. and Brazilian institutions that address public health topics of mutual benefit to both nations
Additional Funding Opportunities

- **AREF/EDCTP Preparatory Fellowships** – Deadline: February 1, 2019
- **TDR Clinical Research and Development Fellowships** – Deadline: March 7, 2019
- **Japan Society for the Promotion of Science (JSPS) Research Fellowships in Japan** – Deadline: March 15, 2019
- **Neglected Tropical Diseases Support Center: Operational Research on "Endgame" Challenges** – No deadline specified

For more information about BVGH FundFinder, please email Cathy Manner.

---

Highlighted Contributions

**Leprosy**

Affecting the skin, peripheral nerves, mucosa of the upper respiratory tract, and eyes, leprosy is an infection caused by the bacteria *Mycobacterium leprae*. If left untreated, the disease can result in progressive and permanent damage to the skin, nerves, limbs, and eyes. Over 200,000 new cases are diagnosed each year, mostly in Brazil, India, and other areas with warm climates.

This Snapshot highlights the following compounds with repurposing potential against *Mycobacterium leprae*:

- Dihydrofolate reductase (DHFR) inhibitors
- HMG-CoA reductase inhibitors
- Phosphoinositide 3-kinase (PI3K) inhibitors
- Squalene synthase inhibitors
- Tyrosine kinase inhibitors

For more information or to discuss potential collaborations involving these compounds, please contact Cathy Manner.

---

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 8-10, 2019</td>
<td>Consortium of Universities for Global Health (CUGH) Annual Conference</td>
<td>Chicago, IL, USA</td>
</tr>
<tr>
<td>March 23-29, 2019</td>
<td>Gordon Research Seminar and Conference: From Innovation in Tropical Infectious Diseases to Global Health Solutions</td>
<td>Galveston, TX, USA</td>
</tr>
<tr>
<td>April 13-16, 2019</td>
<td>European Congress of Clinical Microbiology and Infectious Diseases</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>April 14-17, 2019</td>
<td>World Vaccine Congress Washington</td>
<td>Washington, DC, USA</td>
</tr>
<tr>
<td>May 12-15, 2019</td>
<td>Wellcome Centre for Anti-Infectives Research (WCAIR) Conference on Innovative Drug Discovery and Development</td>
<td>Dundee, UK</td>
</tr>
</tbody>
</table>
Dear WIPO Re:Search Members and Friends,

We are excited to announce that our 2018 BVGH Partnership Hub Annual Report will be released this month! Please keep an eye out for the report in your inboxes next week. While we have far surpassed our 2018 goals for WIPO Re:Search, we look forward to building on these successes and continuing to drive product development for the most pressing global health needs in 2019. If you would like hard copies of the Annual Report, please contact Laurie Pfalzer.

Schistosomiasis affects over 200 million people around the world, and 700 million are at risk for contracting the disease. BVGH recently authored a publication in *Tropical Medicine and Infectious Disease* highlighting the important role WIPO Re:Search and cross-sector partnerships play in combatting schistosomiasis. Read the full publication here.

WIPO Re:Search Members Medicines for Malaria Venture (MMV) and the Drugs for Neglected Diseases initiative (DNDi) recently launched the Pandemic Response Box to provide researchers with free access to 400 diverse antibacterial, antiviral, and antifungal compounds to accelerate the discovery of new treatments for infectious and neglected diseases.

I am pleased to welcome our newest Member to the Consortium, the Puerto Rico Science, Technology & Research Trust (PRSTRT).

As always, please share this Snapshot with your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH

---

**WIPO Re:Search Statistics**

Click here for a list of WIPO Re:Search Members.
Click here for a list of WIPO Re:Search collaborations.
Special Announcement

New Malaria Diagnostic Publication from WIPO Re:Search Collaborators

Hemozoin is a metabolic waste product produced in red blood cells infected by malaria parasites. As part of a collaboration to validate a nonlinear imaging diagnostic tool that would detect hemozoin during malaria parasite infection, Professor Paul Wiseman and Ph.D. student Alexei Kazarine from McGill University were connected with Professor Wellington Oyibo from the University of Lagos in order to have access to, and test clinical samples from, non-infected and malaria-infected patients to identify the limits of detection of this new diagnostic tool. This collaboration has resulted in a publication in Analytical Chemistry. The results demonstrate that this novel diagnostic tool has the potential to easily and rapidly confirm malaria diagnoses following symptoms, and the ability to track treatment progress in existing patients, potentially allowing physicians to adjust medication and dosage for each individual.

Cornerstones of Collaboration

MIT Shares Ampli Blocks to Aid in Onchocerciasis Diagnostic Development

Dr. Stephen Ghogomu at the University of Buea has identified two proteins as potential biomarkers for adult-stage onchocerciasis. To support his diagnostic development, Dr. Jose Gomez-Marquez and Dr. Kimberly Hamad Schifferli at the Massachusetts Institute of Technology (MIT) have shared Ampli Blocks, a set of 40 different building blocks that enable lab workers around the world to assemble them in different ways to produce diagnostic devices. By supplementing the engineering of diagnostic development, Ampli Blocks allow researchers to focus on the biochemistry of detection and promote independent development of site-specific diagnostic devices. Dr. Ghogomu will use these blocks as a platform to develop an onchocerciasis diagnostic device.

Pfizer Provides Expertise in Transdermal Drug Delivery for an Antimalarial Drug Candidate

Dr. Audrey Odom John (Washington University, St. Louis [WUSTL]) and Dr. Cynthia Dowd (The George Washington University [GW]) identified an antimalarial drug candidate with a novel, parasite-specific target. The investigators are
now exploring various solutions to improve the compound’s pharmacokinetic properties, including administration in a patch formulation. BVGH coordinated a call between Dr. Odom John, Dr. Dowd, and Dr. Thean Yeoh, a Pfizer scientist with expertise in transdermal drug delivery, to help assess the feasibility of this approach for the compound.

New Member Announcement

The Puerto Rico Science, Technology & Research Trust (PRSTRT) was created in 2004 by the Commonwealth of Puerto Rico as a non-profit to invest, facilitate, and build capacity to advance Puerto Rico’s economy and well-being through innovation-driven enterprises, science and technology, and its industrial base. As a key component of its work, the Trust engages Puerto Rico’s academic institutions through direct research grant funding and collaborative programmatic initiatives. These include: Brain Trust for Tropical Disease Research and Prevention, Center for Biodiversity and Bioprospecting, Puerto Rico Consortium for Clinical Investigation, Puerto Rico Vector Control Unit, Puerto Rico Public Health Trust, and the Technology Transfer Office, which supports and manages IP and commercialization in partnership with academic research institutions.

BVGH FundFinder Featured Awards

Bill & Melinda Gates Foundation: Neglected Tropical Diseases Data Innovation Incubator

This Grand Challenge seeks innovative ideas for how to improve the quality, completeness, and timeliness of routine NTD data and ensure programmatic decision-making is based on the best available data. Such outcomes will help target interventions to all at-risk populations and achieve high intervention coverage and maximal impact on infection and morbidity.

Amount: $200,000 for up to 6 months (Round 1 – proof of concept); unspecified for 12-18 months (Round 2 – testing solutions broadly)
Organization: Bill & Melinda Gates Foundation
Deadline: March 25, 2019
Eligibility: Open to foreign and domestic organizations; for-profit, non-profit, government, and academic organizations; individuals are not eligible

Additional Funding Opportunities

- [TDR Clinical Research and Development Fellowships](#) – Deadline: March 7, 2019
- [Japan Society for the Promotion of Science (JSPS) Research Fellowships in Japan](#) – Deadline: March 15, 2019
- [MMV 17th Call for Proposals](#) – Deadline: March 29, 2019
- [Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation Medical Research Awards](#) – Deadline: March 31, 2019
- [NIH Global Infectious Disease Research Training Program](#) – Deadline: Letter of Intent due June 25, 2019; Application due July 25, 2019
- [Neglected Tropical Diseases Support Center: Operational Research on "Endgame" Challenges](#) – No deadline specified
For more information about BVGH FundFinder, please email [Cathy Manner](mailto:cathy.manner@bvgh.org).

### Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 8-10, 2019</td>
<td>Consortium of Universities for Global Health (CUGH) Annual Conference</td>
<td>Chicago, IL, USA</td>
</tr>
<tr>
<td>March 23-29, 2019</td>
<td>Gordon Research Seminar and Conference: From Innovation in Tropical Infectious Diseases to Global Health Solutions</td>
<td>Galveston, TX, USA</td>
</tr>
<tr>
<td>April 13-16, 2019</td>
<td>European Congress of Clinical Microbiology and Infectious Diseases</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>April 14-17, 2019</td>
<td>World Vaccine Congress Washington</td>
<td>Washington, DC, USA</td>
</tr>
<tr>
<td>May 12-15, 2019</td>
<td>Wellcome Centre for Anti-Infectives Research (WCAIR) Conference on Innovative Drug Discovery and Development</td>
<td>Dundee, UK</td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada | **MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA.*
Dear WIPO Re:Search Members and Friends,

We are pleased to share the [2018 BVGH Partnership Hub Annual Report](#). In these pages we celebrate the expansion of the WIPO Re:Search portfolio to 140 R&D collaborations focused on improving the prevention, diagnosis, and treatment of some of the world’s most devastating diseases, and the growth of our membership to over 140 organizations across 40 countries. We look forward to building on these successes and continuing to drive product development for the most pressing global health needs.

In honor of International Women’s Day, we also celebrate the Consortium’s achievements in empowering female researchers across the globe and promoting the advancement of women in science. Women account for a minority of the world’s researchers, and we look forward to changing that as we continue our battle against neglected tropical diseases (NTDs), malaria, and tuberculosis.

We enjoyed hosting our partners from the [World Intellectual Property Organization (WIPO)](#) at our Seattle offices in February to discuss WIPO Re:Search strategy and plans for 2019 and beyond.

WIPO Re:Search was recently featured in the [WIPO and the Sustainable Development Goals](#) report, which highlights the many ways that intellectual property (IP) is driving progress toward the Goals by enabling innovation and creativity.

As always, please share this Snapshot with your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent  
President, BVGH

---

**WIPO Re:Search Statistics**

- 148 Agreements Established
- 9 Advancing Agreements
- 55 Active Agreements
- 141 Members
- 41 Countries

Click [here](#) for a list of WIPO Re:Search Members.
Click [here](#) for a list of WIPO Re:Search collaborations.
Click [here](#) to view the WIPO Re:Search Collaboration Pipeline.
Cornerstones of Collaboration

Eisai Shares Compounds to Aid in Leishmaniasis, Malaria, and HAT Drug Discovery

Leishmaniasis, malaria, and human African trypanosomiasis (HAT) are amongst the infectious diseases that disproportionately exact a heavy toll on people living in low- and middle-income countries (LMICs). Professor Fabrice Boyom, head of the Antimicrobial & Biocontrol Agents Unit (AmBcAU) at the University of Yaounde I, is working toward the discovery and development of novel drugs against HAT, leishmaniasis, and malaria by targeting the parasites’ critical metabolic pathways. To support Professor Boyom’s drug discovery efforts, Eisai Co., Ltd. will share dihydrofolate reductase (DHFR) inhibitors and potassium channel blockers.

MSD* Screens Candidates for Tuberculosis Drug Development

It is estimated that one quarter of the world’s population is infected with tuberculosis (TB). To deter the growing threat of multidrug-resistant TB, new treatments are needed to successfully reduce the global burden of this disease. Dr. Cynthia Dowd from The George Washington University has developed lead compounds with anti-tubercular activity, and could be promising candidates for TB drug development. In order to assist Dr. Dowd in target identification, MSD will be screening these compounds to determine their activity against a specific Mycobacterium tuberculosis target.

Dr. Greg Adam, a Principal Scientist in the Early Discovery and In Vitro Pharmacology division at MSD, will be leading the screening efforts to support the testing of Dr. Dowd’s anti-tubercular lead compounds.

*MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA
IP in Focus

The World Intellectual Property Organization (WIPO) offers online tools and training sessions aimed at building human capacity in IP through the WIPO Academy. The Academy is a center of excellence for IP education and training for WIPO member states, particularly developing countries, least-developed countries (LDCs), and countries in transition. The Academy works closely with a number of government and academic partners, and its courses are offered in a range of languages.

BVGH FundFinder Featured Awards

**MMV 17th Call for Proposals**

Medicines for Malaria Venture (MMV) welcomes proposals in the following three areas necessary for the control and eradication of malaria:

- Compounds addressing the key priorities of the malaria eradication agenda
- Compounds having activity against asexual liver and/or blood stages
- Novel approaches for screening

For African malaria researchers in endemic regions, MMV has issued an additional African Call for Proposals.

**Amount:** Unspecified  
**Organization:** MMV  
**Deadline:** March 29, 2019  
**Eligibility:** Unspecified

**Additional Funding Opportunities**

- [ASTMH Annual Meeting Travel Awards](#) – Deadline: March 20, 2019  
- [ASTMH Vulule-Odada Travel Awards for Kenyan Trainees](#) – Deadline: March 20, 2019  
- [NIH Global Infectious Disease Research Training Program](#) – Deadline: Letter of Intent due June 25, 2019; Application due July 25, 2019  
- [Neglected Tropical Diseases Support Center: Operational Research on "Endgame" Challenges](#) – Rolling Deadline
For more information about BVGH FundFinder, please email Cathy Manner.

### Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 13-16, 2019</td>
<td>European Congress of Clinical Microbiology and Infectious Diseases</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>April 14-17, 2019</td>
<td>World Vaccine Congress Washington</td>
<td>Washington, DC, USA</td>
</tr>
<tr>
<td>May 12-15, 2019</td>
<td>Wellcome Centre for Anti-Infectives Research (WCAIR) Conference on Innovative Drug Discovery and Development</td>
<td>Dundee, UK</td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada | **MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA.

Copyright © 2019 BVGH, All rights reserved.

Mailing address: 2101 4th Avenue, Suite 1950, Seattle, WA 98121
Dear WIPO Re:Search Members and Friends,

This month we celebrate two important days that draw attention to the critical role WIPO Re:Search plays in improving global health.

On World Malaria Day (April 25), we reflect on the progress WIPO Re:Search has made toward combating this devastating disease. To date, BVGH has catalyzed more than 45 malaria-focused R&D collaborations, three of which have advanced through development milestones. World Intellectual Property (IP) Day (April 26) celebrates the critical role of IP in stimulating innovation and creativity. Through WIPO Re:Search, BVGH has established 150 IP-sharing collaborations to drive drug, diagnostic, and vaccine development for diseases of poverty, with many more collaborations in development.

Novartis recently joined the Global Chagas Disease Coalition, a collaborative alliance that aims to increase awareness of Chagas disease and foster synergies in disease control, diagnosis, and treatment. Novartis also plans to launch a multinational study of its heart failure drug, Entresto®, in patients with chronic Chagas cardiomyopathy in Latin America. This will be the first definitive morbidity and mortality study to assess a potential cardiac disease therapy in this underserved population.

If you are planning to be in Geneva on April 16, I encourage you to join our WIPO colleagues, Cathy Manner, and me for WIPO’s Global Challenges Seminar on Urgent Innovation: Policies and Practices for Effective Response to Global Health Crises.

I am pleased to welcome our newest WIPO Re:Search Member, Umaru Musa Yar’adua University.

As always, please share this Snapshot with your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH

Special Announcement

New BVGH Publication: “WIPO Re:Search: Catalyzing Public-Private Partnerships to Accelerate Tropical Disease Drug Discovery and Development”

BVGH’s new article in Tropical Medicine and Infectious Disease describes how WIPO Re:Search empowers tropical disease drug discovery researchers from academic and non-profit organizations and small companies to leapfrog their R&D
programs by accessing pharmaceutical industry resources that may not otherwise be available to them. Read the full article here.

WIPO Re:Search Statistics

Cornerstones of Collaboration

**Novartis Shares Compounds to Aid in Chagas Disease Drug Discovery**

It is estimated that eight million people worldwide are infected with *Trypanosoma cruzi*, the causative agent of Chagas disease. In an effort to develop novel drugs against this parasite, Dr. Artur Cordeiro at the Laboratório Nacional de Biociências (LNBio) has identified chemical scaffolds that have shown activity against two promising targets and efficacy against the parasite’s intracellular form. In order to identify additional inhibitors or novel chemical scaffolds with activity against both *T. cruzi* enzymes, Dr. Cordeiro will be working with Novartis as part of their Facilitated Access to Screening Technologies (FAST) Lab program to screen several of Novartis’ proprietary compounds against these two targets to identify tool compounds for structure-based drug discovery.

**University of Dundee Provides Training to Support Leishmaniasis R&D**

Leishmaniasis is endemic in nearly 100 countries worldwide and, with treatment failure a growing problem, there is an urgent need for development of novel first-line agents. Dr. Edmund Ekuadzi, co-manager of the Kwame Nkrumah University of Science and Technology (KNUST) Central Laboratory and former Novartis Next Generation Scientist...
Program fellow, is exploring the anti-leishmanial properties of Ghanaian plants used in traditional medicines. He will receive training in bioassay-guided fractionation of plant extracts through the Wellcome Centre for Anti-Infectives Research (WCAIR) program at the University of Dundee to advance his drug discovery programs.

Partnership Hub Central

Advancing Healthcare Innovation in Africa (AHIA) 2019 – Apply by April 15!

Led by Emory University and the Southern Africa Network for Biosciences (SANBio), AHIA is a transformative program for healthcare scientists in Africa. Its goal is to support and promote the advancement of health innovations and technologies in Africa by advising, educating, and training African scientists in the business and legal aspects of the healthcare sector.

AHIA is a multi-phase program that consists of a three-day conference (July 10-12, 2019, in Johannesburg, South Africa)—during which development plans will be created for each participant’s technology—and ongoing advice from leading scientific, business, and legal professionals. AHIA is a non-profit and does not take any ownership in any project.

African scientists with innovative solutions to healthcare needs on the African continent are invited to apply here.

New Member Announcement

Umaru Musa Yar’adua University (UMYU), formerly known as Katsina State University, was established under the Katsina State Law No. 7 of September 2006. The Katsina State University was conceived to serve as a nucleus for socio-economic, technological, and political development of the State by producing highly skilled human resources through conventional face-to-face and distance learning modes. It is the hope and aspiration of the Government and people of Katsina State to establish, nurture, and develop a world-class university driven by modern information and communication technology (ICT) culture.

BVGH FundFinder Featured Awards

Harrington Scholar-Innovator Award

The Harrington Scholar-Innovator Award recognizes physician-scientist innovators whose research has the potential to change standards of care. The award provides research and drug development support to help bridge the gap between basic discovery and the clinical realm.

Amount: US$100,000, with opportunity to qualify for up to US$700,000
Organization: Harrington Discovery Institute
Deadline: May 3, 2019
Eligibility: Must have M.D. or M.D./Ph.D. and hold a faculty position at an accredited academic medical center, university or research institution in the US or Canada

Additional Funding Opportunities

- Wellcome Trust: International Master’s Fellowships – Deadline: April 16, 2019
- Wellcome Trust: International Intermediate Fellowships – Deadline: April 25, 2019
- Wellcome Trust: International Training Fellowships – Deadline: April 25, 2019
- NIH Global Infectious Disease Research Training Program – Deadline: Letter of Intent due June 25, 2019; application due July 25, 2019

For more information about BVGH FundFinder, please email Cathy Manner.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 12-15, 2019</td>
<td>Wellcome Centre for Anti-Infectives Research (WCAIR) Conference on Innovative Drug Discovery and Development</td>
<td>Dundee, UK</td>
</tr>
<tr>
<td>June 3-6, 2019</td>
<td>BIO International Convention</td>
<td>Philadelphia, PA, USA</td>
</tr>
<tr>
<td>Sept. 10-13, 2019</td>
<td>20th International Leprosy Congress</td>
<td>Manila, Philippines</td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada | **MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA.
Dear WIPO Re:Search Members and Friends,

This month WIPO Re:Search celebrates a major milestone – the establishment of our 150th collaboration! We are proud of the growth of the WIPO Re:Search portfolio and global network over the last seven years, and of the dedicated investigators who work each day to combat antimicrobial resistance and address other unmet medical needs for neglected diseases. We look forward to seeing their efforts translate into better drugs, diagnostics, and vaccines that will save lives and drive progress toward the United Nations Sustainable Development Goals.

Cathy Manner and I enjoyed seeing many of our partners in Geneva last month at WIPO’s Global Challenges Seminar on Urgent Innovation: Policies and Practices for Effective Response to Global Health Crises. Speakers included representatives from WIPO Re:Search Members Drugs for Neglected Diseases initiative (DNDi) and MSD, as well as the World Health Organization (a special technical advisor to WIPO Re:Search).

As always, please share this Snapshot with your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent
President, BVGH

WIPO Re:Search Statistics

Click here for a list of WIPO Re:Search Members.
Click here for a list of WIPO Re:Search collaborations.
Click here to view the WIPO Re:Search Collaboration Pipeline.
Cornerstones of Collaboration

Pfizer Provides Compounds to Support the Development of Novel Antimalarials

Dr. Hoseah Akala and Reagan Mogire at the Kenya Medical Research Institute (KEMRI) are working towards the discovery and development of novel drugs against malaria. Using a target-similarity approach, their study identified several essential *Plasmodium falciparum* proteins that could potentially be targeted by commercially available drugs created for other diseases. In order to continue these studies and validate the predicted targets, they requested additional compounds to test their activity against these predicted targets. To support their efforts, Pfizer, Inc., has shared several compounds from various chemical classes that could potentially be repurposed for malaria drug discovery.

Takeda Shares Compounds to Aid in Leishmaniasis Drug Discovery

Takeda will be sharing MAP kinase inhibitors with Dr. Tanya Parish and Dr. Samuel Njikan at the Infectious Disease Research Institute (IDRI) to support their leishmaniasis drug discovery efforts.

Advancing Collaboration: Eisai and University of California, San Diego

In follow-up to a prior agreement, Eisai Co., Ltd. will provide Prof. Conor Caffrey, Nematode and Trematode Core Director at the Center for Discovery and Innovation in Parasitic Diseases at the University of California, San Diego (UCSD), with an additional set of targeted inhibitors to screen against *Schistosoma mansoni*.

BVGH FundFinder Featured Awards
Call for Proposals on Intervention Effectiveness

The Neglected Tropical Diseases Support Center (NTD-SC) at The Task Force for Global Health is soliciting proposals for operational and implementation research to improve the effectiveness of interventions used in the elimination of neglected tropical diseases (NTDs). Research proposed for this call will investigate and solve persistent challenges associated with the implementation of NTD programs, focusing on different elements of either mass drug administration (MDA) or morbidity management and disability prevention (MMDP).

Amount: Not specified
Organization: Neglected Tropical Diseases Support Center
Deadline: Priority – June 3, 2019; Regular – July 31, 2019
Eligibility: Proposals must be nested within national programs and target lymphatic filariasis, onchocerciasis, schistosomiasis, or trachoma

Additional Funding Opportunities

- Atomwise Artificial Intelligence Molecular Screen (AIMS) Awards Program – Deadline: May 31, 2019
- NIH Global Infectious Disease Research Training Program – Deadline: Letter of Intent due June 25, 2019; application due July 25, 2019

For more information about BVGH FundFinder, please email Cathy Manner.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 3-6, 2019</td>
<td>BIO International Convention</td>
<td>Philadelphia, PA, USA</td>
</tr>
<tr>
<td>Sept. 2-6, 2019</td>
<td>19th International Vaccinology Course</td>
<td>Seoul, South Korea</td>
</tr>
<tr>
<td>Sept. 10-13, 2019</td>
<td>20th International Leprosy Congress</td>
<td>Manila, Philippines</td>
</tr>
<tr>
<td>Sept. 26-28, 2019</td>
<td>East African Research in Progress 2019</td>
<td>Moshi, Tanzania</td>
</tr>
</tbody>
</table>
*Known as EMD in the US and Canada | **MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA.
Dear WIPO Re:Search Members and Friends,

It is hard to believe we are nearly halfway through 2019! With 13 targeted collaborations established so far, multiple communications pieces completed and in development, and recruitment of new Latin American Members in full swing, BVGH is well on track to meet – and even surpass – our goals for the year.

WHO recently released its first snakebite strategy, targeting a 50 percent reduction in deaths and disabilities caused by snakebite envenoming over the next 12 years. This news aligns with the announcement of an £80 million program by Wellcome Trust to change the way snakebite treatments are researched and delivered. The goal of this important new initiative is to make snakebite treatments safer and more accessible to those who need them most. If you are a snakebite researcher, I encourage you to email Cathy Manner to discuss opportunities to advance your work through WIPO Re:Search.

WIPO’s new interactive web story illustrates how WIPO Re:Search and the WIPO Re:Search Fellowship Program are driving progress towards the United Nations Sustainable Development Goals (SDGs).

As always, please share this Snapshot with your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH

---

**Special Announcement**

**WIPO Re:Search: Advancing Science for Neglected Tropical Diseases, Malaria, and Tuberculosis**

In the latest publication in the Global Challenges in Focus series, WIPO takes an in-depth look at some of WIPO Re:Search’s most promising scientific collaborations and their potential impacts – as described by the researchers and organizations involved. Read here.
Cornerstones of Collaboration

**GSK Provides Compound Library to Aid in Malaria Drug Discovery Efforts**

GSK will be sharing its TCAMS compound library with Drs. Audrey Odom John and Paul Hruz at Washington University in St. Louis (WUSTL) for screening for antimalarial drug discovery.

**GIBH and University of Yaoundé I Partner to Test a Novel Antibiotic for Buruli Ulcer**

Dr. Tianyu Zhang, Principal Investigator and Director of the National Key Laboratory for Respiratory Diseases at Guangzhou Institutes of Biomedicine and Health (GIBH), is exploring the bactericidal activity of the antibiotic candidate TB47 against Buruli ulcer. He will send TB47 to Dr. Fabrice Boyom at the University of Yaoundé I for further testing against clinical Mycobacterium ulcerans strains.
IP in Focus

WIPO Summer Schools on Intellectual Property

The WIPO Summer Schools provide an opportunity for university students and young professionals to acquire a deeper knowledge of IP, and how it can be used as a tool for sustainable development, as well as the role of WIPO in the administration and the provision of global IP services. Register here.

BVGH FundFinder Featured Awards

EDCTP Opens Four Major Calls for Proposals

The European and Developing Countries Clinical Trials Partnership (EDCTP) is opening four major calls for Research and Innovation Actions (clinical trials) this month. These calls aim to support projects that include clinical trials.

- **Pediatric Drug Formulations for Poverty-Related Diseases** – Deadline: October 10, 2019
- **Strategic Actions on Product-Related Implementation Research** – Deadline: October 10, 2019
- **New Drugs and Vaccines for Priority Pathogens in Antimicrobial Resistance** – Deadline: November 7, 2019
- **Strategic Actions Supporting Large-Scale Clinical Trials** – Deadline: November 7, 2019

Additional Funding Opportunities

- **NIH Global Infectious Disease Research Training Program** – Deadline: Letter of Intent due June 25, 2019; application due July 25, 2019
- **ASTMH Centennial Travel Award in Basic Science Tropical Disease Research** – Deadline: July 10, 2019
- **AAS Affiliates Program** – Deadline: July 15, 2019
- **Neglected Tropical Diseases Support Center Call for Proposals on Intervention Effectiveness** – Deadline: July 31, 2019

For more information about BVGH FundFinder, please email Cathy Manner.
# Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept. 2-6, 2019</td>
<td>IVI International Vaccinology Course</td>
<td>Seoul, South Korea</td>
</tr>
<tr>
<td>Sept. 10-13, 2019</td>
<td>International Leprosy Congress</td>
<td>Manila, Philippines</td>
</tr>
<tr>
<td>Sept. 16-20, 2019</td>
<td>European Congress on Tropical Medicine and International Health*</td>
<td>Liverpool, UK</td>
</tr>
<tr>
<td>Sept. 26-28, 2019</td>
<td>East African Research in Progress</td>
<td>Moshi, Tanzania</td>
</tr>
<tr>
<td>Oct. 17-20, 2019</td>
<td>IEEE Global Humanitarian Technology Conference*</td>
<td>Seattle, WA, USA</td>
</tr>
<tr>
<td>Oct. 27-29, 2019</td>
<td>World Health Summit</td>
<td>Berlin, Germany</td>
</tr>
<tr>
<td>Nov. 20-24, 2019</td>
<td>ASTMH Annual Meeting*</td>
<td>National Harbor, MD, USA</td>
</tr>
</tbody>
</table>

*BVGH anticipated to attend

---

*Known as EMD in the US and Canada | **MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA.

---

Copyright © 2019 BVGH, All rights reserved.

Mailing address: 2101 4th Avenue, Suite 1950, Seattle, WA 98121
Dear WIPO Re:Search Members and Friends,

This month we celebrate a 91 percent reduction in the number of people at risk of trachoma, the world’s leading infectious cause of blindness. This success against trachoma underscores the importance of global partnerships for developing innovative solutions against neglected infectious diseases and delivering those solutions to those who need them most. If you are a trachoma researcher, I encourage you to contact Cathy Manner about potential research collaborations to further your work.

**Medicines for Malaria Venture (MMV)** has released a new *P. vivax information hub*. The website contains key learnings, best practices, tools, and resources from a consortium of stakeholders involved in the treatment and control of *P. vivax* malaria.

**TDR** and **WHO** have developed a new training course on ethics in implementation research to ensure appropriate engagement with research subjects and communities and to safeguard against potential harm. The training course was launched at the [Global Conference on Implementation Science and Scale-Up](#) in Bangladesh.

Congratulations to Dr. Dawn Wetzel at **University of Texas Southwestern Medical Center**, who has received a Harrington Scholar-Innovator Award that will support her ongoing WIPO Re:Search collaborations.

As always, please share this Snapshot with your colleagues and reach out to us with any partnering requests or ideas.

*Sincerely,*

Jennifer Dent
President, BVGH
Cornerstones of Collaboration

Eisai Bolsters Award-Winning Scientist’s Antiparasitic Drug Discovery Programs

Dr. Dawn Wetzel at the University of Texas Southwestern Medical Center—a 2019 Harrington Scholar-Innovator Award recipient—has identified a specific class of inhibitors with biological activity against *Leishmania* parasites. In order to support Dr. Wetzel’s antiparasitic screening efforts, Eisai Co., Ltd. has agreed to share inhibitors from this class of compounds.

Johnson & Johnson (J&J) Partners with a Nigerian Researcher to Discover Novel Antimalarials

J&J will be sharing a phenotypic screening library with Dr. Lawal Bilbis at Usman Danfodiyo University, Sokoto (UDUS), for screening for antimalarial drug discovery.
RSTMH and LSTM Open Nominations for the Hemingway Award 2019

Fellows and members of the Royal Society of Tropical Medicine and Hygiene (RSTMH) and students, alumni, or staff members of the Liverpool School of Tropical Medicine (LSTM) are invited to nominate candidates for the Hemingway Award 2019. This Award is to recognize Professor Janet Hemingway’s achievements in delivering and encouraging translational science during her leadership of LSTM.

Amount: £5,000 cash prize
Organization: RSTMH/LSTM
Deadline: July 22, 2019, 17:00 UK time
Eligibility: Nominees can be researchers, scientists, and professionals from anywhere in the world, with no restriction on age or sector.

Additional Funding Opportunities

- EDCTP Pediatric Drug Formulations for Poverty-Related Diseases – Deadline: October 10, 2019
- EDCTP Strategic Actions on Product-Related Implementation Research – Deadline: October 10, 2019
- EDCTP New Drugs and Vaccines for Priority Pathogens in Antimicrobial Resistance – Deadline: November 7, 2019
- EDCTP Strategic Actions Supporting Large-Scale Clinical Trials – Deadline: November 7, 2019
- EDCTP Career Development Fellowships – Deadline: November 27, 2019
- EDCTP Preparatory Fellowships: Joint Call with the Africa Research Excellence Fund (AREF) – Deadline: November 27, 2019

For more information about BVGH FundFinder, please email Cathy Manner.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept. 2-6, 2019</td>
<td><a href="#">IVI International Vaccinology Course</a></td>
<td>Seoul, South Korea</td>
</tr>
<tr>
<td>Sept. 10-13, 2019</td>
<td><a href="#">International Leprosy Congress</a></td>
<td>Manila, Philippines</td>
</tr>
<tr>
<td>Sept. 16-20, 2019</td>
<td><a href="#">European Congress on Tropical Medicine and International Health</a></td>
<td>Liverpool, UK</td>
</tr>
<tr>
<td>Sept. 26-28, 2019</td>
<td><a href="#">East African Research in Progress</a></td>
<td>Moshi, Tanzania</td>
</tr>
<tr>
<td>Oct. 17-20, 2019</td>
<td><a href="#">IEEE Global Humanitarian Technology Conference</a></td>
<td>Seattle, WA, USA</td>
</tr>
<tr>
<td>Oct. 27-29, 2019</td>
<td><a href="#">World Health Summit</a></td>
<td>Berlin, Germany</td>
</tr>
<tr>
<td>Nov. 20-24, 2019</td>
<td><a href="#">ASTMH Annual Meeting</a></td>
<td>National Harbor, MD, USA</td>
</tr>
</tbody>
</table>

* BVGH anticipated to attend
Dear WIPO Re:Search Members and Friends,

It is hard to believe we are more than halfway through the year! The 2019 BVGH Partnership Hub Mid-Year Report is coming soon with exciting news about the progress WIPO Re:Search is making toward controlling and eliminating neglected infectious diseases. We have established 15 collaborations to date in 2019 - exceeding our annual objective already! Latin American Member recruitment is in full swing to fill the gap in regional representation.

Fiocruz and The Global Health Network have formed a new strategic partnership to amplify the impact of Fiocruz’s health research and capacity development initiatives. The partnership will promote research capacity building across Portuguese-speaking countries and enable research findings from the Zika outbreak to benefit public health worldwide.

I am pleased to welcome our newest Member, International Centre for Genetic Engineering and Biotechnology (ICGEB), to the Consortium.

As always, please share this Snapshot with your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH

WIPO Re:Search Statistics

Click here for a list of WIPO Re:Search Members.
Click here for a list of WIPO Re:Search collaborations.
Click here to view the WIPO Re:Search Collaboration Pipeline.
Cornerstones of Collaboration

Medicines for Malaria Venture (MMV) Supports Antimalarial Drug Development Program

MMV will assess the solubility and metabolic stability of lead antimalarial compounds from Dr. Adam Renslo at the University of California, San Francisco through in vitro studies.

Johnson & Johnson (J&J) Accelerates Schistosomiasis Drug Discovery Efforts

J&J will be sharing a highly annotated phenotypic compound library with Dr. Conor Caffrey at the University of California, San Diego to screen for schistosomiasis drug discovery.

New Member Announcement

International Centre for Genetic Engineering and Biotechnology (ICGEB)

Established as a special project of the United Nations Industrial Development Organization (UNIDO) in 1983, and fully autonomous since 1994, ICGEB is a unique intergovernmental organization that runs laboratories in Trieste, Italy; New Delhi, India; and Cape Town, South Africa; and forms an interactive network with over 65 Member States. ICGEB’s headquarters in Trieste are fully equipped to undertake modern molecular and cellular biology research. Currently, more than 200 people make up the 18 Research Groups that operate out of ICGEB Trieste. Research programs include basic science projects such as control of gene expression, DNA replication, DNA repair, and RNA processing; studies on human viruses such as HIV, human papillomavirus (HPV), and rotavirus; molecular immunology; neurobiology; molecular genetics; experimental hematology; and human gene therapy. The research undertaken at the Cape Town and New Delhi campuses focuses on key needs of African and Indian populations, with groups focusing on malaria, tuberculosis, biopesticides, cancer genomics, and cytokines and disease.
The purpose of this call for proposals is to fund projects that are designed to support sub-Saharan African countries to establish and/or develop robust national medicines regulatory systems and capacities for ethical review of clinical research and use of medicinal products and technologies in humans, as well as national and international collaboration in compliance with established, internationally acceptable good practices. This scheme targets projects with the active involvement of national ethics committees (NECs) and/or National Regulatory Authorities (NRAs) from countries with both weak and strong ethics and regulatory capacities in sub-Saharan Africa.

**Amount:** Up to €500,000  
**Organization:** EDCTP  
**Deadline:** November 21, 2019  
**Eligibility:** Must have active involvement of the NECs/NRAs of a sub-Saharan African country

### Additional Funding Opportunities

- **GHIT Fund Discovery Investment Target Research Platform** – Deadline: August 27, 2019  
- **GHIT Fund Product Development Platform** – Deadline: August 27, 2019  
- **COR-NTD Call for Proposals on Health Systems Strengthening** – Deadline: August 30, 2019  
- **GHIT Fund Hit-to-Lead Platform** – Deadline: September 2, 2019  
- **EDCTP Pediatric Drug Formulations for Poverty-Related Diseases** – Deadline: October 10, 2019  
- **EDCTP Strategic Actions on Product-Related Implementation Research** – Deadline: October 10, 2019  
- **EDCTP New Drugs and Vaccines for Priority Pathogens in Antimicrobial Resistance** – Deadline: November 7, 2019  
- **EDCTP Strategic Actions Supporting Large-Scale Clinical Trials** – Deadline: November 7, 2019  
- **EDCTP Career Development Fellowships** – Deadline: November 27, 2019  
- **EDCTP Preparatory Fellowships: Joint Call with the Africa Research Excellence Fund (AREF)** – Deadline: November 27, 2019

For more information about BVGH FundFinder, please email [Cathy Manner](mailto:Cathy.Manner@edctp.org).

---

### Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept. 2-6, 2019</td>
<td><a href="https://www.ivipl.edu/en/education/ivipl-course">IVI International Vaccinology Course</a></td>
<td>Seoul, South Korea</td>
</tr>
<tr>
<td>Sept. 10-13, 2019</td>
<td><a href="https://www.who.int/leprosy/en/events/2019/">International Leprosy Congress</a></td>
<td>Manila, Philippines</td>
</tr>
<tr>
<td>Sept. 16-20, 2019</td>
<td><a href="https://www.who.int/medicine/en/">European Congress on Tropical Medicine and International Health</a></td>
<td>Liverpool, UK</td>
</tr>
<tr>
<td>Date</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>Sept. 26-28, 2019</td>
<td>East African Research in Progress</td>
<td>Moshi, Tanzania</td>
</tr>
<tr>
<td>Oct. 17-20, 2019</td>
<td>IEEE Global Humanitarian Technology Conference*</td>
<td>Seattle, WA, USA</td>
</tr>
<tr>
<td>Oct. 27-29, 2019</td>
<td>World Health Summit</td>
<td>Berlin, Germany</td>
</tr>
<tr>
<td>Nov. 9-10, 2019</td>
<td>Woman Leaders in Global Health Conference</td>
<td>Kigali, Rwanda</td>
</tr>
<tr>
<td>Nov. 20-24, 2019</td>
<td>ASTMH Annual Meeting*</td>
<td>National Harbor, MD, USA</td>
</tr>
</tbody>
</table>

*BVGH anticipated to attend

*Known as EMD in the USA and Canada | **MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA.

Copyright © 2019 BVGH, All rights reserved.

Mailing address: 2101 4th Avenue, Suite 1950, Seattle, WA 98121
Dear WIPO Re:Search Members and Friends,

We are excited to announce the release of our [BVGH Partnership Hub Mid-Year Report 2019](#)! Over the first half of the year, BVGH established 14 collaborations, recruited two new Members, and shared WIPO Re:Search successes globally through peer-reviewed publications ([one of which](#) was recently reprinted in a book, *Prospects for Schistosomiasis Elimination*) and social media. Read the Report to learn how the BVGH team is well on its way to achieving and surpassing its 2019 goals and deliverables.

This year marks the establishment of the 150th WIPO Re:Search collaboration. WIPO published an [article](#) commemorating this important milestone and showcasing the efforts of our Members—including Eisai and MSD*— to develop better treatments for malaria, tuberculosis, and neglected tropical diseases. An [interview](#) with Amy Dietterich, Director of the Global Challenges Division at WIPO, highlights the critical role of the WIPO Re:Search intellectual property-sharing platform in catalyzing new solutions for diseases of poverty.

Joseph Hargan-Calvopiña will be representing BVGH and coordinating a WIPO Re:Search panel session at the [European Congress on Tropical Medicine and International Health](#) in Liverpool, UK, this month. The session is titled *Neglected Disease R&D Through the Lens of a Public-Private Partnership Model*. Please [email](#) Joseph if you would like to schedule a time to meet at the conference.

As always, please share this Snapshot with your colleagues and reach out to us with any partnering requests or ideas.

*Sincerely,*

*Jennifer Dent*

*President, BVGH*

---

*MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA*
WIPO Re:Search Statistics

Click [here](#) for a list of WIPO Re:Search Members.
Click [here](#) for a list of WIPO Re:Search collaborations.
Click [here](#) to view the WIPO Re:Search Collaboration Pipeline.

IP in Focus

**WIPO Patent Drafting Training Program**

WIPO offers [tailor-made workshops](#) to help inventors and other users of the patent system improve their patent drafting skills and techniques. These events are organized in collaboration with member states, national and regional intellectual property offices and institutions.

Scheduled Workshops:

- [WIPO Sub-Regional Patent Drafting Workshop](#) (Amman, Jordan)  
  *October 13-17, 2019*
- [WIPO National Patent Drafting Workshop](#) (Mexico)  
  *October 21-25, 2019*

**WIPO-WHO-WTO Trilateral Symposium (October 31, 2019; Geneva, Switzerland)**

The 8th Joint Technical Symposium will address the importance of innovation in, and access to, cutting-edge health technologies to ensure progress towards universal health coverage and the achievement of the health-related UN Sustainable Development Goals. The draft program is available [here](#). Online registration is available [here](#).

Cornerstones of Collaboration

**Academic-Industry Partnership Pursues Schistosomiasis Drug Discovery**
Praziquantel was discovered 40 years ago and remains the only available treatment for schistosomiasis, a disease that affects 240 million people globally. Through WIPO Re:Search, investigators from Seattle Children’s Research Institute (SCRI) and the NIAID-funded Seattle Structural Genomics Center for Infectious Disease (SSGCID) are working to solve the crystal structure for Schistosoma HMG-CoA reductase (SmHMGR), a promising drug target. To support these efforts, MSD* scientists developed and shared codon-optimized SmHMGR gene constructs for expressing the SmHMGR protein and solving its crystal structure. With a crystal structure, Dr. Conor Caffrey at the University of California, San Diego plans to carry out rational drug design and optimization of SmHMGR inhibitors.

Maria Kornienko, an Associate Principal Scientist in the Screening and Protein Science division at MSD*, played a key role in generating the codon-optimized gene constructs to support SSGCID’s structural elucidation efforts for the SmHMGR protein.

*MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA

---

**Partnership Hub Central**

**Novartis Next Generation Scientist Fellow Receives Travel Grant to Attend ASTMH 2019**

Dr. Peter Mubanga Cheuka, a lecturer and malaria researcher at the University of Zambia, was awarded an American Society of Tropical Medicine and Hygiene (ASTMH) travel grant to attend the organization’s annual meeting in November. Dr. Cheuka, who participated in the Novartis Next Generation Scientist Program, will be presenting his research at the meeting.

Dr. Cheuka received recognition of this achievement from his institution’s Vice-Chancellor, Professor Luke Evuta Mumba.
The African Research Network for Neglected Tropical Diseases (ARNTD) with support from the U.S. Agency for International Development (USAID) and UK aid from the UK government, through the Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD), is seeking proposals for both operational and social science research on "Emerging challenges facing NTD program implementation in Africa." This third edition of the Small Grants Program (SGP III) is to support African researchers in both early and mid/late career to undertake operational research aligned with the goals established in the London Declaration on Neglected Tropical Diseases.

**Amount:** Up to US $25,000 per award  
**Organization:** NTD Support Center  
**Deadline:** September 30, 2019  
**Eligibility:** Researchers and academics based in research institutions or universities in Africa

### Additional Funding Opportunities

- [EDCTP Pediatric Drug Formulations for Poverty-Related Diseases](#) – Deadline: October 10, 2019  
- [EDCTP Strategic Actions on Product-Related Implementation Research](#) – Deadline: October 10, 2019  
- [NIH Planning Grant for Global Infectious Disease Research Training Program](#) – Deadline: Letter of intent due on October 12, 2019  
- [EDCTP New Drugs and Vaccines for Priority Pathogens in Antimicrobial Resistance](#) – Deadline: November 7, 2019  
- [EDCTP Strategic Actions Supporting Large-Scale Clinical Trials](#) – Deadline: November 7, 2019  
- [EDCTP Ethics and Regulatory Capabilities 2019](#) – Deadline: November 21, 2019  
- [EDCTP Career Development Fellowships](#) – Deadline: November 27, 2019  
- [EDCTP Preparatory Fellowships: Joint Call with the Africa Research Excellence Fund (AREF)](#) – Deadline: November 27, 2019

For more information about BVGH FundFinder, please email [Cathy Manner](mailto:).
| Oct. 17-20, 2019 | **IEEE Global Humanitarian Technology Conference** | Seattle, WA, USA |
| Oct. 27-29, 2019 | **World Health Summit** | Berlin, Germany |
| Oct. 31, 2019 | **WIPO-WHO-WTO Trilateral Symposium** | Geneva, Switzerland |
| Nov. 9-10, 2019 | **Woman Leaders in Global Health Conference** | Kigali, Rwanda |
| Nov. 20-24, 2019 | **ASTMH Annual Meeting** | National Harbor, MD, USA |

* BVGH anticipated to attend

*Known as EMD in the USA and Canada | **MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA.
Dear WIPO Re:Search Members and Friends,

I know I was not alone in watching with keen interest the United Nations General Assembly in September. The spotlight that the General Assembly shines on the Sustainable Development Goals (SDGs) reminds us of the important work that we do day in and day out to improve the lives of people around the world. WIPO Re:Search Members and friends like you are truly instrumental to advancing the UN’s SDGs around health and well-being, innovation, and global partnerships.

At this moment, the Assemblies of the Member States of WIPO are meeting in Geneva to address the opportunities and challenges of intellectual property. We know that intellectual property is not a barrier to global health innovation, but instead is a key ingredient. WIPO Re:Search demonstrates this fact. The WIPO Re:Search consortium of Member companies and institutions around the world continually show that public-private partnerships are making smart use of intellectual property to address neglected infectious diseases. This Snapshot newsletter gives you a peek into our Members’ work happening around malaria, tuberculosis, and Buruli ulcer. To learn more about how the Consortium is contributing to the SDGs, I encourage you to read WIPO’s recent article, SDG Spotlight: Health Innovation to Treat Neglected Diseases.

Later this month, Analise LeJeune-Stodieck will be representing BVGH and presenting a session at the IEEE Global Humanitarian Technology Conference in Seattle. Joseph Hargan-Calvopiña and Noah Hunthausen will be attending the ASTMH Annual Meeting next month in National Harbor, Maryland. Please email Analise, Joseph or Noah if you would like to schedule a time to meet at these conferences.

Through these global events and the work of WIPO Re:Search, we are all united in our commitment to address and end the scourge of infectious diseases.

As always, please share this Snapshot with your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent
President, BVGH
IP in Focus

**WIPO Patent Drafting Training Program**

WIPO offers [tailor-made workshops](#) to help inventors and other users of the patent system improve their patent drafting skills and techniques. These events are organized in collaboration with member states, national and regional intellectual property offices and institutions.

Scheduled Workshops:

- [WIPO Sub-Regional Patent Drafting Workshop](#) (Amman, Jordan)
  - October 13-17, 2019
- [WIPO National Patent Drafting Workshop](#) (Mexico)
  - October 21-25, 2019

**WIPO-WHO-WTO Trilateral Symposium (October 31, 2019; Geneva, Switzerland)**

The [8th Joint Technical Symposium](#) will address the importance of innovation in, and access to, cutting-edge health technologies to ensure progress towards universal health coverage and the achievement of the health-related UN Sustainable Development Goals. Online registration is available [here](#).
Cornerstones of Collaboration

By Speeding TB Diagnoses, Researchers Aim to Save Lives

Although tuberculosis (TB) is the leading infectious disease killer in the world, early diagnosis and treatment can prevent most TB deaths. Dr. Abraham Pinter at the Public Health Research Institute at Rutgers New Jersey Medical School, along with colleagues at the Foundation For Innovative New Diagnostics (FIND), are using novel monoclonal antibodies isolated from TB-infected patients for a diagnostic assay that is more sensitive and has a similar high level of specificity than currently available assays. In order to further improve the sensitivity of the assay, Dr. Pinter has connected with Dr. Peter Myler and fellow investigators from the NIAID-funded Seattle Structural Genomics Center for Infectious Disease (SSGCID) at Seattle Children’s Research Institute (SCRI) to solve the crystal structure of these antibodies complexed to their antigens. These crystal structures will guide computational methods to design sequence variations that increase the affinity and/or specificity of the existing antibodies. This work will provide the foundation for an improved diagnostic test that can quickly, easily, and inexpensively identify TB infection in people.

Merck KGaA and University of Yaoundé I Take on Buruli Ulcer

Merck KGaA*, Darmstadt, Germany will be sharing its Mini Library with Professor Fabrice Boyom at University of Yaoundé I for Buruli ulcer drug discovery.

* Known as EMD is the USA and Canada
Publication Looks at Resistance-Causing Malaria Genes

Dr. Jun-Hu Chen at the National Institute of Parasitic Diseases (NIPD) has developed PCR assays to identify resistance-causing mutations in malaria parasite genes. With funding from NIPD, Uche Igbasi, a graduate student in the laboratory of Dr. Wellington Oyibo at the University of Lagos, spent two months at NIPD to receive training on the PCR assay while using samples from Nigerian patients to look for mutations causing resistance to drugs. This collaboration resulted in a publication titled, "Kelch 13 propeller gene polymorphism among Plasmodium falciparum isolates in Lagos, Nigeria: molecular epidemiologic study" that demonstrates that although three mutant genotypes of Kelch 13 gene were observed, no validated Kelch 13 polymorphism associated with artemisinin resistance was seen.

Rutgers TB Researcher Accepted into Atomwise Award program

WIPO Re:Search investigator Dr. G. Marcela Rodriguez from the Public Health Research Institute at Rutgers New Jersey Medical School has been accepted into Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program. Dr. Rodriguez has identified a promising drug target in M. tuberculosis, and now, through the AIMS program, Artificial Intelligence will perform a virtual screen of more than 10 million compounds. She will then be provided with 72 small molecules predicted to bind her protein target, and will have support from Atomwise’s medicinal chemists and computational biologists.

WIPO Re:Search Scientist wins Grand Challenges Africa Award

Professor Fabrice Boyom from University of Yaoundé I in Cameroon is one of eight African drug discovery researchers who were awarded up to US $100,000 to expand their research capacity. The Grand Challenges Africa award is made possible through a partnership with Medicines for Malaria Venture (MMV), University of Cape Town’s H3D, and the Bill & Melinda Gates Foundation. The award aims to advance the discovery of new drugs to prevent, treat, and cure diseases endemic to Africa. Learn more at MMV.

SDG Spotlight: Health Innovation to Treat Neglected Diseases

In September, world leaders gathered at the United Nations (UN) Headquarters in New York to signal how they will boost action to respond to the climate emergency and ensure the health and wellbeing of people everywhere. WIPO Re:Search contributes to the UN SDGs by encouraging the sharing of intellectual property-protected health assets and know-how. Learn more at the World Intellectual Property Organization (WIPO).
The African Academy of Sciences (AAS), the National Institutes of Health (NIH), and the Bill & Melinda Gates Foundation are partnering under the auspices of the Coalition of African Research and Innovation (CARI) to establish a post-doctoral training fellowship program, the African Postdoctoral Training Initiative (APTI).

APTI fellows will train in a global health research area of priority for their home institutions and countries, and AAS, BMGF and NIH, while building bridges and lasting connections between the partner organizations and African scientists and institutions. While at the NIH, the fellows must be on leave or sabbatical from their home institution under the NIH Intramural Visiting Fellow Program. The research priority areas are in infectious diseases, nutrition, and reproductive, maternal, and child health and developing skills for clinical and translational research.

Funding call: African Postdoctoral Training Initiative (APTI) requirements, selection criteria, FAQs and application
Organization: The AAS
Application deadline: December 1, 2019

Additional Funding Opportunities

- [EDCTP Pediatric Drug Formulations for Poverty-Related Diseases](#) – Deadline: October 10, 2019
- [EDCTP Strategic Actions on Product-Related Implementation Research](#) – Deadline: October 10, 2019
- [NIH Planning Grant for Global Infectious Disease Research Training Program](#) – Deadline: Letter of intent due October 12, 2019
- [Chevening Scholarships](#) – Deadline: November 5, 2019
- [EDCTP New Drugs and Vaccines for Priority Pathogens in Antimicrobial Resistance](#) – Deadline: November 7, 2019
- [EDCTP Strategic Actions Supporting Large-Scale Clinical Trials](#) – Deadline: November 7, 2019
- [EDCTP Career Development Fellowships](#) – Deadline: November 27, 2019
- [EDCTP Preparatory Fellowships: Joint Call with the Africa Research Excellence Fund (AREF)](#) – Deadline: November 27, 2019

For more information about BVGH FundFinder, please email Cathy Manner.
## Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oct. 9-10, 2019</td>
<td>The Global Fund’s Sixth Replenishment Conference</td>
<td>Lyon, France</td>
</tr>
<tr>
<td>Oct. 17-20, 2019</td>
<td>IEEE Global Humanitarian Technology Conference*</td>
<td>Seattle, WA, USA</td>
</tr>
<tr>
<td>Oct. 27-29, 2019</td>
<td>World Health Summit</td>
<td>Berlin, Germany</td>
</tr>
<tr>
<td>Oct. 31, 2019</td>
<td>WIPO-WHO-WTO Trilateral Symposium</td>
<td>Geneva, Switzerland</td>
</tr>
<tr>
<td>Nov. 9-10, 2019</td>
<td>Women Leaders in Global Health Conference</td>
<td>Kigali, Rwanda</td>
</tr>
<tr>
<td>Nov. 12-14, 2019</td>
<td>NIMR 6th International Scientific Conference</td>
<td>Lagos, Nigeria</td>
</tr>
<tr>
<td>Nov. 20-24, 2019</td>
<td>ASTMH Annual Meeting*</td>
<td>National Harbor, MD, USA</td>
</tr>
</tbody>
</table>

*BVGH anticipated to attend

*Known as EMD in the USA and Canada | **MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA.
November 2019

Dear WIPO Re:Search Members and Friends,

Seizing upon the power of global partnerships and innovation forms the heart of WIPO Re:Search’s mission to improve health around the world. Collaboration — especially partnerships across sectors and geographies — is essential to addressing neglected tropical diseases, malaria, and tuberculosis, which know no boundaries and affect billions of people across the globe. BIO Ventures for Global Health (BVGH) staff continually establish and nurture critical global partnerships, having formalized relationships with research institutions in 42 countries and counting across six continents.

This month, I am pleased to announce our newest WIPO Re:Search Member from Latin America, Institut Pasteur de Montevideo, our first Member in Uruguay. This recruitment is part of our ongoing efforts to expand WIPO Re:Search activities in Latin America. The addition of Institut Pasteur de Montevideo to the Consortium exemplifies how WIPO Re:Search finds the centers of excellence needed to accelerate neglected disease R&D in partnership with our Member companies Eisai; GSK; Johnson & Johnson; Merck KGaA, Darmstadt, Germany; MSD*; Novartis, Pfizer, and Takeda.

Our friends at IFPMA feature WIPO Re:Search and the public-private partnership activities of our Member companies and organizations in their new knowledge hub, Global Health Progress. This excellent resource shows how global partnerships such as WIPO Re:Search are supporting the Sustainable Development Goals.

This month, BVGH’s Joseph Hargan-Calvopiña and Noah Hunthausen will be attending the ASTMH Annual Meeting in National Harbor, Maryland. Please email Joseph or Noah if you would like to schedule a time to meet at the conference to discuss WIPO Re:Search partnering opportunities.

As always, please share this Snapshot with your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent

President and CEO, BVGH
New Member Announcement

Welcome Institut Pasteur de Montevideo — our first Member from Uruguay!

The Institut Pasteur de Montevideo (IP Montevideo) in Uruguay is one of the most recent affiliates of the Institut Pasteur International Network, composed of 33 independent centers located on five continents and united by the same values. Dedicated to scientific research in biomedicine, IP Montevideo comprises high-tech scientific platforms in areas such as genomics, proteomics, bioinformatics, and molecular and cellular biology. It serves as an international education center with courses on the latest biological knowledge and state-of-the-art technologies, with laboratories open to young scientists’ research projects. Additionally, IP Montevideo promotes start-ups for the development of biotechnological applications.

Cornerstones of Collaboration

Takeda and IDRI Advance Leishmaniasis Drug Discovery Efforts

After the Infectious Disease Research Institute (IDRI) received positive screening results from the originally shared MAP kinase inhibitors, Takeda is resupplying hit compounds in continued support of their leishmaniasis drug discovery efforts.
Partnership Hub Central

Eisai, GSK, and Johnson & Johnson Featured in Panel at ECTMIH

During the 11th European Congress on Tropical Medicine and International Health (ECTMIH) in Liverpool, UK, BVGH hosted a panel session titled “Neglected Disease R&D Through the Lens of a Public-Private Partnership Model.” Panelists from academic organizations in the US and UK highlighted how the sharing of intellectual property assets can accelerate innovation for neglected disease R&D. They discussed their collaborations with pharmaceutical company Members through WIPO Re:Search.

Dr. Audrey Odom John spoke about her collaborations with Johnson & Johnson and GSK focused on malaria drug discovery. Dr. Paul Jackson discussed how the Janssen Pharmaceutical Companies of Johnson & Johnson have leveraged BVGH’s network in order to establish successful collaborations around neglected infectious diseases through WIPO Re:Search. Professor Alister Craig discussed his collaboration with Eisai Co., Ltd., relating to novel therapeutic targets for cerebral malaria. Dr. Jose Gomez-Marquez highlighted his work in diagnostics through the Little Devices Lab at MIT. Dr. Peter Hotez shared insights regarding vaccine development for diseases of poverty.

This month, BVGH will promote the power of public-private partnerships and the sharing of intellectual property assets for neglected disease R&D at the ASTMH Annual Meeting in National Harbor, MD. We look forward to meeting with investigators interested in exploring cross-sector collaborations to advance their research. To set up a meeting, please contact Joseph Hargan-Calvopiña at jhargan@bvgh.org or Noah Hunthausen at Nhunthausen@bvgh.org.

WIPO Re:Search Collaboration Studies K13 Mutations in Cameroon

Artemisinin resistance has been documented in Southeast Asia, and there is significant concern that such resistance may spread to Africa. Researchers have identified Plasmodium falciparum K13 mutations as molecular markers of artemisinin resistance in Southeast Asia. BVGH connected Dr. Fang Huang at the National Institute of Parasitic Diseases and Dr. Carole Eboumbou at the Centre Pasteur du Cameroun through WIPO Re:Search to study K13 mutations in three epidemiologically distinct regions in Cameroon. The collaborators recently published a paper that details the mutations identified from the analysis of 175 blood samples and concludes that “non-synonymous K13 mutations are still rare and highly diverse” in Cameroon. Read the paper in PLoS ONE.

WIPO Re:Search Featured in Global Health Progress

WIPO Re:Search Member organization IFPMA has launched Global Health Progress, a knowledge hub that highlights cross-sector industry contributions to the Sustainable Development Goals (SDGs). A goal of Global Health Progress is to drive new and existing collaborations to support the SDGs, with a particular focus on SDG 17: Partnerships for the Goals. With a knowledge hub of over 200 collaborations, Global Health Progress features WIPO Re:Search and the public-private partnership activities of our Member companies and organizations.
The purpose of this call for proposals is to support early to mid-career researchers ("fellows") by providing them an opportunity to train and develop their clinical research skills. The objectives are: (1) to promote retention of postdoctoral researchers and postgraduate medical researchers in the research field of sub-Saharan Africa; and (2) to equip the fellows to establish themselves as independent researchers with ability to initiate their own research teams at host institutions in sub-Saharan Africa.

**Call Budget:** €3.25 million  
**Expected Number of Grants:** 16-20  
**Organization:** EDCTP  
**Deadline:** November 27, 2019

### Additional Funding Opportunities

- **EDCTP Preparatory Fellowships: Joint Call with the Africa Research Excellence Fund (AREF)** – Deadline: November 27, 2019
- **The AAS African Postdoctoral Training Initiative (APTI)** – Deadline: December 1, 2019
- **NIH Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines** – Letter of Intent Due: December 17, 2019; Application Deadline: January 17, 2020
- **EDCTP Senior Fellowships Plus 2019** – Deadline: February 1, 2020

For more information about BVGH FundFinder, please email Cathy Manner.

### Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nov. 21-22, 2019</td>
<td><strong>2nd International Conference on Tropical and Infectious Diseases</strong></td>
<td>Bali, Indonesia</td>
</tr>
<tr>
<td>Date</td>
<td>Event Description</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Nov. 20-24, 2019</td>
<td><strong>ASTMH Annual Meeting</strong></td>
<td>National Harbor, MD, USA</td>
</tr>
<tr>
<td>Dec. 4-6, 2019</td>
<td><strong>1st International Conference on NTDs in Africa</strong></td>
<td>Nairobi, Kenya</td>
</tr>
<tr>
<td>Dec. 8-12, 2019</td>
<td><strong>Keystone Symposia: Helminths: New Insights from Immunity to Global Health</strong></td>
<td>Cape Town, South Africa</td>
</tr>
<tr>
<td>Jan. 16-20, 2020</td>
<td><strong>Keystone Symposia: Tuberculosis: Immunity and Immune Evasion</strong></td>
<td>Santa Fe, NM, USA</td>
</tr>
</tbody>
</table>

*BVGH anticipated to attend*
December 2019

Dear WIPO Re:Search Members and Friends,

How is intellectual property a driver of — and not a barrier to — solutions for neglected tropical diseases, malaria, and tuberculosis? Since 2011, pharmaceutical companies and research institutions have been answering that question by participating in the WIPO Re:Search Consortium. Through the sharing of existing drugs and industry know-how with talented researchers, our Members are finding novel uses of drugs for diseases of the world’s poor. In essence, Consortium Members are seizing the promise of open innovation.

To see what open innovation through WIPO Re:Search looks like in practice, take a look at our two newest publications. The first highlights WIPO Re:Search partnership stories from 2016 to 2019. The second publication looks at seven collaborations that have been advancing solutions for neglected infectious diseases along the product development pathway. Throughout these publications, we feature R&D partnerships made possible by our industry Members Eisai; GSK; Johnson & Johnson; Merck KGaA, Darmstadt, Germany; MSD*; Novartis, Pfizer, and Takeda.

We continue to expand Consortium activities in Latin America. Our newest WIPO Re:Search Member is the University of Puerto Rico, our second Member from the island Commonwealth.

As always, please share this Snapshot with your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent, President & CEO
BIO Ventures for Global Health

*MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA
New Member Announcement

Welcome University of Puerto Rico – Our Second Member From the Island!

The University of Puerto Rico (UPR) is the main public university system of Puerto Rico. It consists of 11 campuses and has approximately 58,000 students and 5,300 faculty members. UPR is the leader in research on the island and houses the majority of specialized equipment and facilities. As an important center of scientific activity for graduate students, UPR is the main producer of highly trained staff for corporations, industry, and government. Together with its research partners, which include the government sector, companies, industry, and community organizations, UPR is working to build a bright future for Puerto Rico.

Partnership Hub Central

New NIH Tools Will Help Guide Clinical Researchers

NIH has added new resources to its popular NCCIH Clinical Research Toolbox. The web-based Toolbox contains templates, sample forms, protocols, and guidelines — including Clinical Research Start Up resources — to assist investigators in the development and conduct of high-quality clinical research studies. While the Toolbox is geared toward investigators funded by the National Center for Complementary and Integrative Health (NCCIH), many of the guidelines and templates should be helpful for all clinical investigators.

Learn more in the NCCIH Research Blog
New Publications

**WIPO Re:Search Partnership Stories 2016-2019**

BVGH brings to life the WIPO Re:Search portfolio of 155 R&D collaborations focused on improving the prevention, diagnosis, and treatment of some of the world’s most-devastating diseases. The stories show how global cross-sector collaborations are driving R&D for neglected infectious diseases.

Member companies featured include Eisai; GSK; Johnson & Johnson; Merck KGaA, Darmstadt, Germany; MSD*; Novartis, Pfizer, and Takeda.

[Read the publication](#)

*MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA

**WIPO Re:Search: Advancing Product Development for Neglected Infectious Diseases through Global Public-Private Partnerships**

This new publication features seven promising WIPO Re:Search drug development collaborations that have advanced through key R&D milestones.

[Read the publication](#)

BVGH FundFinder Featured Awards

**U.S.-Japan Cooperative Medical Sciences Program (USJCMSP) Collaborative Awards**

CRDF Global is accepting proposals from joint U.S., Japan, and other Regional Asia-Pacific (APac)-based investigators working in the field of infectious disease and immunology research. The purpose of the USJCMSP collaborative awards is to foster new or expanded viral disease and immunology-focused biomedical research collaborations between researchers in Japan, the APac region, and U.S. investigators and institutions. It is expected that proposals will focus on questions of direct relevance to the APac region that will add to global knowledge about viral diseases and immunology. The USJCMSP continues to promote collaborations, especially to include early-stage and female scientists from around the region.
Awards: Up to US $60,000 each
Expected Number of Awards: 6-8
Deadline: Monday, March 16, 2020, 11:59 p.m. U.S. Eastern Time

Additional Funding Opportunities

- **NTD-SC Research to Address the Challenges and Inequities Presented by Female Genital Schistosomiasis (FGS)** – Deadline: December 31, 2019
- **EDCTP Senior Fellowships Plus 2019** – Deadline: February 1, 2020
- **JSPS Research Fellowships in Japan (Extramural)** – Deadline: March 31, 2020

For more information about BVGH FundFinder, please email [Cathy Manner](mailto:Cathy.Manner@bvhfundfinder.org).

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan. 16-20, 2020</td>
<td><strong>Keystone Symposia: Tuberculosis: Immunity and Immune Evasion</strong></td>
<td>Santa Fe, NM, USA</td>
</tr>
<tr>
<td>Feb. 20-23, 2020</td>
<td><strong>19th International Congress on Infectious Diseases</strong></td>
<td>Kuala Lumpur, Malaysia</td>
</tr>
<tr>
<td>Feb. 23-27, 2020</td>
<td><strong>Molecular Approaches to Malaria (MAM) 2020</strong></td>
<td>Lorne, Victoria, Australia</td>
</tr>
<tr>
<td>June 1-12, 2020</td>
<td><strong>6th McGill Summer Institute in Infectious Diseases and Global Health (Now accepting applications)</strong></td>
<td>Montreal, QC, Canada</td>
</tr>
</tbody>
</table>